Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol

INTRODUCTION: There is no curative treatment available for patients with chemotherapy relapsed or refractory CD19+ B cells-derived acute lymphoblastic leukaemia (r/r B-ALL). Although CD19-targeting second-generation (2nd-G) chimeric antigen receptor (CAR)-modified T cells carrying CD28 or 4-1BB doma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiao-Yi, Sun, Yao, Zhang, Ang, Hu, Guo-Liang, Cao, Wei, Wang, Dan-Hong, Zhang, Bin, Chen, Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223707/
https://www.ncbi.nlm.nih.gov/pubmed/28039295
http://dx.doi.org/10.1136/bmjopen-2016-013904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223707/
https://www.ncbi.nlm.nih.gov/pubmed/28039295
http://dx.doi.org/10.1136/bmjopen-2016-013904

Ejemplares similares